【佳学基因检测】GPNMB、EGFR、p-PI3K和Ki-67在食管鳞状细胞癌患者中的预后价值

全国十大肿瘤基因检测公司排名解释

小组讨论博士医师年度双基练习《肿瘤靶向药物的敏感性及有效性》《Anal Cell Pathol (Amst)》在. 2022 Aug 31;2022:9303081.发表了一篇题目为《GPNMB、EGFR、p-PI3K和Ki-67在食管鳞状细胞癌患者中的预后价值》肿瘤靶向药物治疗基因检测临床研究文章。该研究由Bo Wang, Mengyan Li, Anna Su, Yongmei Gao, Yan Shi, Chao Li, Wenying Liu, Liping Su, Wan Li, Yuqing Ma 等完成。促进了肿瘤的精准治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤靶向药物及精准治疗临床研究内容关键词：

肿瘤靶向治疗基因检测临床应用结果

背景：GPNMB 是一种新发现的促肿瘤因子，可通过 EGFR 激活 PI3K/AKT 通路促进肿瘤细胞进展。然而，关于 ESCC 中 GPNMB 的研究不足。本研究探讨了食管鳞癌中GPNMB与EGFR/PI3K通路基因的关系。方法：采用免疫组织化学方法检测GPNMB、EGFR、p-PI3K和Ki-67的表达水平。采用SPSS 22.0和R进行统计分析。结果：与癌旁组织相比，ESCC中GPNMB mRNA的表达更高。 GPNMB 上调样本中 EGFR、PIK3CA、PIK3CB 和 AKT1 的表达增加。 GPNMB 表达与 EGFR、p-PI3K 和 Ki-67 表达呈正相关。 GPNMB 在 AJCC III 期、淋巴结转移和中低分化患者中表达较高。 EGFR在血管侵犯患者中表达较高； p-PI3K在哈萨克语中的表达高于汉族； Ki-67 在肿瘤大小≥ 3 cm 时表达较高。 GPNMB、p-PI3K 和 Ki-67 高表达的患者 总生存期 较差。 p-PI3K、Ki-67、神经侵犯和淋巴转移是ESCC的独立危险因素，术后辅助治疗是ESCC的保护因素。结论：GPNMB作为促癌因子，有望成为ESCC的潜在靶点。

肿瘤发生与复发转移国际数据库描述：

Background: GPNMB is a newly discovered tumour-promoting factor that may promote tumour cell progression by activating the PI3K/AKT pathway by EGFR. However, there are insufficient studies about GPNMB in ESCC. This study investigated the relationship between GPNMB and EGFR/PI3K pathway genes in ESCC.Methods: The expression levels of GPNMB, EGFR, p-PI3K, and Ki-67 were examined using immunohistochemistry. Statistical analysis was done by SPSS 22.0 and R.Results: GPNMB mRNA expression is higher in ESCC compared with paracancerous tissues. The expression of EGFR, PIK3CA, PIK3CB, and AKT1 was increased in GPNMB upregulated samples. GPNMB expression was positively correlated with EGFR, p-PI3K, and Ki-67 expression. GPNMB was expressed higher in the AJCC III stage, lymph node metastasis, and moderately poorly differentiated patients. EGFR was higher expressed in patients with vascular invasion; p-PI3K expression in Kazak was higher than that in Han; Ki-67 expression was higher in tumour size ≥ 3 cm. Patients with high expression of GPNMB, p-PI3K, and Ki-67 had worse OS. p-PI3K, Ki-67, nerve invasion, and lymphatic metastasis were independent risk factors, and postoperative adjuvant therapy was a protective factor in ESCC.Conclusion: As a tumour-promoting factor, GPNMB is expected to be a potential target for ESCC.